Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
B-Cell Chronic Lymphocytic Leukemia - Overview
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
B-Cell Chronic Lymphocytic Leukemia - Drug Profiles
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
Featured News & Press Releases
Feb 03, 2020: Calibr’s ?switchable’ CAR-T platform for cancer moves forward with FDA clearance of Investigatiol New Drug application
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Alexion Pharmaceuticals Inc, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BeiGene Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioIntegrator, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioInvent International AB, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Biosplice Therapeutics Inc, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioXpress Therapeutics SA, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Bristol-Myers Squibb Co, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Chengdu USino Technology Biology Co Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by CRISPR Therapeutics AG, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Hangzhou Hezheng Pharmaceutical Co Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Kuur Therapeutics Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Loxo Oncology Inc, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Mediolanum farmaceutici SpA, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Merck & Co Inc, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nkarta Inc, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nordic Nanovector ASA, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Tianweiyuan and Biomedicine Shanghai Co Ltd, 2022
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, 2022
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, 2022 (Contd..1)
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, 2022 (Contd..2)
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, 2022